Tenofovir disoproxil
- Generic Name
- Tenofovir disoproxil
- Brand Names
- Atripla, Cimduo, Complera, Delstrigo, Stribild, Symfi, Truvada, Viread, Tenofovir disoproxil Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C19H30N5O10P
- CAS Number
- 201341-05-1
- Unique Ingredient Identifier
- F4YU4LON7I
- Background
Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name Viread, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). This drug is prescribed in combination with other drugs for the management of HIV infection as well as for Hepatitis B therapy. Tenofovir disoproxil was initially approved in 2001 .
- Indication
Tenofovir disoproxil is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients ≥2 years old and weighing ≥10 kg. It is also indicated for the treatment of chronic hepatitis B in patients ≥2 years old and weighing ≥10 kg.
Tenofovir disoproxil is also an ingredient in several combination products, all of which are indicated either alone or in combination with other antiretrovirals for the treatment of HIV-1 infection.
In addition, tenofovir disoproxil is available in combination with emtricitabine (under the brand name Truvada) for use as pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents weighing ≥ 35kg to reduce the risk of sexually-acquired HIV-1 infection.
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis
- Conditions
- Hepatitis BLiver Fibrosis
- Interventions
- Drug: PEG-Interferon alfa 2a
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 186
- Registration Number
- NCT03957629
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
- Conditions
- Hepatitis BAcute-On-Chronic Liver Failure
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 150
- Registration Number
- NCT03920618
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis
- Conditions
- Liver FibrosisHepatitis B
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 100
- Registration Number
- NCT03920605
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis
- Conditions
- Liver FibrosisHepatitis B
- Interventions
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 120
- Registration Number
- NCT03919565
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 2600
- Registration Number
- NCT03915964
- Locations
- 🇺🇸
Hope Research Institute, Phoenix, Arizona, United States
🇨🇿Clintrial s.r.o., Praha, Praha 10, Czechia
🇨🇿Revmatologie MUDr. Štejfová, Praha, Praha 4, Czechia
Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 963
- Registration Number
- NCT03903796
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
- Conditions
- Hepatitis B InfectionMalignant Solid Neoplasm
- Interventions
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 4
- Registration Number
- NCT03887702
- Locations
- 🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Health Partners Inc, Minneapolis, Minnesota, United States
Faecal Analyses in Rheumatoid Arthritis Therapy
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Region Skane
- Target Recruit Count
- 50
- Registration Number
- NCT03775824
A Study to Investigate the Safety, Efficacy and PK of Multiple Doses of QL-007 in Chronic Hepatitis B Patients in CHINA
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03770624
- Locations
- 🇨🇳
Peking University First Hospital, Peking, Beijing, China
A Drug-drug Interaction (DDI) Study of Morphothiadine Mesilate/Ritonavir in Healthy Subjects
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT03662568
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.